Allied Minds will henceforth operate without a chief executive after Joseph Pignato announced his decision to resign.

Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.

Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.

Leigh Brody and Dominik Leisi have joined Albion Capital to work on the life science investment team for UCL Technology Fund.

The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.

Luba Greenwood has been brought on to run Binney Street Capital on behalf of cancer research and care provider Dana-Farber Cancer Institute.

Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.

Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.

University of Michigan and Virginia-founded Everactive has reached its series C target after three tranches.